NCT04478279: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only HR+ breast cancer patients are eligible for the expansion phase
Exclusions: Patients with untreated unstable central nervous system (CNS) metastases and/or leptomeningeal disease – see trial for details; For the expansion phase, patients must have progressed after prior 1-2 hormone-based therapies

Comments are closed.

Up ↑